BioNTech Price Target Cut at Citi Following Co-Founder NewsIn a notable development for shareholders of the German biotechnology giant, Citi has revised its financial outlook for BioNTech SE (NASDAQ: BNTX) . The financial services firm announced it is lowering its price target on the company's shares to $130 from $145 , a reduction of approximately 10%. Despite this downward adjustment to the valuation metric, Citi has opted to maintain its Buy rating on the stock, signaling a nuanced perspective on the company's current trajectory.
The decision to trim the price target comes in the wake of a significant corporate shake-up: the planned departure of BioNTech's co-founders, Prof. Ugur Sahin and Dr. Özlem Türeci, from their active executive roles. The analyst leading the coverage acknowledges that this leadership transition caught the market by surprise, introducing an element of uncertainty that has weighed on investor sentiment. However, Citi views the resulting selloff in BioNTech's shares not as a signal of fundamental deterioration, but as a potential opportunity for investors.
In a detailed research note issued to clients, the analyst explains that while the co-founders' move to new advisory capacities represents a major change, the company's underlying value driver—its deep and advancing pipeline—remains intact and robust. The firm is emphasizing that BioNTech’s research and development portfolio features multiple assets that are currently in Phase 3 clinical trials. This late-stage pipeline density is critical, as it represents a diversified range of potential oncology catalysts that could drive the next wave of growth for the company, reducing its historical reliance on revenue from its COVID-19 vaccine partnership with Pfizer.
Citi’s commentary suggests that the current market reaction may be overweighing the leadership risk while underappreciating the scientific progress within the company. By keeping a Buy rating alongside a reduced (but still premium) price target, the firm is effectively arguing that the risk/reward profile has improved at the lower share price. For long-term investors, the note implies that the recent volatility offers a compelling entry point to gain exposure to BioNTech’s high-potential oncology pipeline, which is steadily advancing toward potential commercialization.
Long
